Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adma Biologics (ADMA) Inventory (2016 - 2025)

Adma Biologics' Inventory history spans 14 years, with the latest figure at $206.5 million for Q4 2025.

  • For Q4 2025, Inventory rose 21.28% year-over-year to $206.5 million; the TTM value through Dec 2025 reached $206.5 million, up 21.28%, while the annual FY2025 figure was $206.5 million, 21.28% up from the prior year.
  • Inventory reached $206.5 million in Q4 2025 per ADMA's latest filing, up from $196.7 million in the prior quarter.
  • In the past five years, Inventory ranged from a high of $206.5 million in Q4 2025 to a low of $94.1 million in Q1 2021.
  • Average Inventory over 5 years is $158.6 million, with a median of $163.6 million recorded in 2022.
  • Peak YoY movement for Inventory: skyrocketed 80.05% in 2021, then decreased 3.12% in 2025.
  • A 5-year view of Inventory shows it stood at $124.7 million in 2021, then surged by 30.91% to $163.3 million in 2022, then increased by 5.9% to $172.9 million in 2023, then decreased by 1.54% to $170.2 million in 2024, then increased by 21.28% to $206.5 million in 2025.
  • Per Business Quant, the three most recent readings for ADMA's Inventory are $206.5 million (Q4 2025), $196.7 million (Q3 2025), and $191.5 million (Q2 2025).